Objectives: to determine the clinical outcome of subintimal angioplasty (SA) and to assess impact on surgical workload. Design: retrospective review of a single radiologist's case series. Materials: one hundred and twenty two patients with critical limb ischaemia and 26 with claudication. Methods: one hundred and fifty eight limbs treated by SA. Main outcome measures: technical success and complications; cumulative patency, limb salvage and survival; affect of SA on vascular workload. Results: the technical success rate was 85%. There were 26 procedural complications (16%) but no patient required emergency surgery; 30-day mortality was 3%. Primary and secondary 12-month patency rates were 27 and 33%. Limb salvage rate was 88% at 12 months. SA initially reduced the number of patients needing arterial surgery, although this then increased due to late failure of SA and an increase in de novo bypass. Conclusions: SA carries a low risk of major complications and high immediate technical success. Poor long-term patency suggests that SA is not as durable as bypass surgery. However, failed SA did not compromise subsequent surgery, which only became necessary in a proportion of patients. Our data suggests that there is little to be lost by using SA as first-line treatment for patients with limb-threatening ischaemia who are poor operative risks or who have no autologous vein available.
Introduction
The role of percutaneous transluminal angioplasty (PTA) for intermittent claudication remains controversial despite 35 years' clinical experience. A recent Cochrane review concluded that angioplasty confers no clinical benefit for mild to moderate claudication. 1 This summarised results from two randomisedcontrolled trials comparing angioplasty to exercise training. 2, 3 However, angioplasty continues to be used in an ad hoc way, in spite of increasing evidence suggesting that claudicants are best treated conservatively with anti-platelet therapy, cardiovascular risk reduction and exercise training. 4 Critical limb ischaemia (CLI) has an annual incidence of 400 per million population in the U.K. 5 By definition, treatment is needed for limb salvage. Frequently, patients present with diffuse femoropopliteal or infra-popliteal disease: the recent TransAtlantic Inter-Society Consensus document (TASC) concludes that these are best treated by surgery, where possible. 6 However, surgery represents a physiological challenge to this, often frail group of patients. Subintimal angioplasty (SA), pioneered by the Leicester group in the U.K. 7 can treat more complex disease patterns than conventional PTA, broadening the indications for endovascular treatment. Computer modelling has shown that angioplasty for ischaemic rest pain can increase quality-adjusted life expectancy and decrease lifetime treatment cost compared to surgery. 8 However, several retrospective studies have shown that despite increased use of PTA, the rate of surgery continues to rise while the major amputation rate is unchanged. 9, 10 No series has included the effect of SA on clinical practice. The aim of this study was therefore to determine the clinical outcome of SA in our unit and to determine the impact on surgical workload.
Method
SA was introduced into clinical practice in this hospital in 1997. Diagnostic angiograms were reviewed at the multidisciplinary vascular meeting. All cases potentially treatable by SA underwent this procedure, including those suitable for bypass surgery, but excluding lesions treatable by PTA. Data was extracted from a consecutive series of 166 limbs (156 patients) treated by a single interventional radiologist, including the learning curve. Eight patients treated with iliac SA were excluded from further analysis. The procedure was carried out using a standardised technique. 7 Indications for treatment were CLI or lifestyle-limiting claudication. Hospital notes were reviewed retrospectively and patients were invited to re-attend for outpatient follow-up. Grading of limb ischaemia and angioplasty patency rates were reported according to the revised SVS/ISCVS criteria 11 and the TASC document. 6 For purposes of this study, claudication grades 1 to 3 were defined according to patient-reported walking distances of 4250 m, 50±200 m and 550 m respectively. Shortterm patency required an angiographic improvement (530% residual stenosis), an increase in anklebrachial pressure index (ABPI) by 40.1 and an improvement in clinical category. 11 For tissue loss, this required complete ulcer healing. Long-term patency was defined as maintenance of both the improvement in clinical category and the increased ABPI ( 0.1 below maximum post-angioplasty value). Duplex ultrasound was used to confirm patency if there was a reduction in ABPI. However, any deterioration in clinical status was considered as a treatment failure. All results were reported as intention to treat. Data was analysed using the life-table method and patency curves compared with the Mantel±Haenszel test.
Corresponding data on surgical and radiological workload for CLI between 1996 and 1999 was extracted from a prospectively gathered departmental database.
Results

Subintimal angioplasty
One hundred and forty eight patients (55% men, 45% women) underwent SA between 1997 and 1999. The median (interquartile range (IQR)) age was 77.5 (70±82) years. Demographic data are shown in Table 1 . Sixty-four patients (43%) were taking low-dose aspirin while a further 13 (9%) were intolerant of aspirin. All patients were prescribed aspirin after the procedure unless intolerant. Fifty-four patients (36%) had previously undergone intervention for lower limb ischaemia, including ipsilateral angioplasty in 26 cases and surgery in three cases.
There were 29 claudicant limbs in 26 patients (Rutherford grades 1 to 3) with a median (IQR) reported walking distance of 51 m (23±91). There were 129 limbs with CLI in 122 patients. One hundred and one limbs had tissue loss (Rutherford grade 5) with peripheral gangrene in six cases and ischaemic ulceration in the remainder. Twenty eight limbs had rest pain alone (Rutherford grade 4), while a further 51 had rest pain and tissue loss with a median (IQR) duration of 7 weeks (3 weeks to 4 months). The median (IQR) ABPI was 0.55 (0.40±0.66) with an absolute ankle systolic pressure of 80 mmHg (61±110).
Diagnostic angiography revealed 135 arterial occlusions and 12 stenoses, with no information available on 11 limbs. The median occlusion length was 10 cm (IQR 5±16, range 3±60). This was distributed in the femoro-popliteal segment in 122 (77%) and crural vessels in 36 (23%). According to TASC morphology 12 lesions were graded as Type A in one limb, B in The site of entry into the subintimal plane and reentry back into the vessel lumen is shown in Table 2 . The technical success rate of the procedure was 85%. Of 23 technical failures, most were due to failed creation of a subintimal plane (n 10) or failed re-entry back into the lumen (n 7). The subintimal channel collapsed in four patients and immediately thrombosed in one patient. There was significant vessel perforation in three patients, leading to abandonment of the procedure. Nine technical failures required no further intervention while three proceeded to major amputation. Eleven patients subsequently underwent successful bypass surgery: one graft later occluded, requiring a below knee amputation at two months. The complication rate from the procedure was 16% (26 limbs): haematoma (n 12), vessel perforation (n 8), thrombosis (n 3), distal embolus (n 1), vessel spasm (n 1) and myocardial infarction (n 1). No patient required emergency surgery for a procedurerelated complication, and seven patients underwent successful immediate endovascular treatment.
Early results
The median (IQR) increase in ABPI following the procedure was 0.18 (0±0.40). At 30 days, 21 limbs were normalised (asymptomatic with an ABPI 4 1.0) and 43 limbs improved in both ABPI and clinical category. Twenty-six limbs showed either an improvement in ABPI or clinical category, and are therefore not strictlỳ`p atent'' according to the SVS/ISCVS criteria. 11 There was no change of clinical category in 47 limbs and a deterioration of ABPI and/or clinical category in 13 limbs. Overall, 30-day primary and secondary patency rates by strict criteria were 45 and 46% respectively. Thirty-day mortality was 3% (four patients), all in technical successes. The cause of death was myocardial infarction (n 1), cardiac failure (n 1) and of uncertain aetiology (n 2). Fig. 1 . Six patients were excluded from the life-tables because of missing data. There was an obvious attrition rate from 1 month onwards, with primary and secondary patency rates of 27 and 33% at 12 months. Patency rates in claudicants and those with CLI were not statistically different: primary patency 48% vs 24% at 12 months (Mantel±Haenszel, chi-squared 3.60, p 5 0.10) (Fig. 2) ; secondary patency 58% vs 28% at 12 months (chi-squared 3.07, p 5 0.10). There was no statistical difference in primary patency at 12 months in limbs with crural vessel disease (16%) vs femoro-popliteal segment disease (30%) (chi-squared 1.74, p 4 0.10). Run-off had no significant effect on patency rates. Primary patency at 12 months was 32, 21, 28 and 40% with zero, one, two and three run-off vessels respectively (Mantel± Haenszel chi-squared 2.91, p 4 0.10). Did the learning curve affect patency rates? The series was analysed according to``early'' (1997±1998, 83 cases) There were no amputations in the claudicants. Despite poor patency in those with CLI, the cumulative limb salvage rate was 86 and 84% at one and two years (Fig. 3) . Twelve month limb salvage was similar in both femoro-popliteal and crural segments (89% vs 85%) and``early'' and``late'' cases respectively (87% vs 89%). Fifteen patients (10%) required a major amputation during the study period. Seven patients underwent primary amputation, three in technical failures and four following reocclusion of a previously dilated segment. The remaining eight patients underwent surgical (n 7 femoro-popliteal/distal bypass) or radiological intervention (repeat SA) before undergoing major amputation at a median 6 months following initial SA. Cumulative 2-year survival was 97% in claudicants and 60% in those with CLI. The single death in the claudicant group was due to a myocardial infarction at 30 days.
Follow-up
Patients were assessed by clinical and haemodynamic criteria. Those with an improved clinical category but a decrease 4 0.1 in post-angioplasty ABPI were further investigated with Duplex ultrasound (n 26) or angiography (n 3). Cumulative primary and secondary patency rates according to the life-table method are shown in
Clinical workload
Workload patterns for SA, PTA, bypass surgery and major amputation for chronic lower limb ischaemia are shown in Figure 4 . Introduction of SA led to a slight decline in numbers of PTA and major amputations. There was a fall in surgical bypass procedures in the year after SA was introduced (1998) although in the following year numbers increased above baseline. This is a reflection of secondary reconstruction following failed SA (n 22, 1999) but also an increase in de novo bypass i.e. patients who had not undergone previous SA (n 92, 1999). This represents an increase in overall workload for chronic lower limb ischaemia, i.e. 114 cases in 1997, 151 cases in 1998 and 189 cases in 1999.
Discussion
Subintimal angioplasty attempts to overcome the problems of PTA by creating a smooth neo-lumen. The technique was initially described by Bolia et al. in Leicester for femoro-popliteal and crural lesions 7 and has been extended to iliac occlusions. 13 SA is undoubtedly operator-dependent. Anecdotal reports suggest that the most frequent technical problem is failure to re-enter the vessel lumen distal to the disease. Two cases of spontaneous communication between the neo-lumen and the true lumen following failed SA have been described. 14 Despite good technical success, the patency rates in this series are disappointing and are not influenced by symptoms, level of disease or infrapopliteal run-off, although a type II error cannot be excluded. However, patency may be underestimated due to the rigorous SVS/ISCVS reporting criteria. For example, complete ulcer healing is required to achieve clinical patency, which excludes patients who show signs of ulcer healing. Six patients had a significant improvement in ABPI following SA, although still had active ulceration. These were considered as``occluded'' in the analyses. As this was a retrospective study, it is difficult to ascertain whether these ulcers were purely ischaemic, or whether there was another component, e.g. venous disease. Nonetheless, patients required intervention on clinical grounds.
Technical success rates of 76±80% can be achieved with SA of femoro-popliteal lesions. 15, 16 Of these technical successes, up to 84% show clinical improvement at 6 months. 15 The Leicester series of 200 consecutive femoro-popliteal occlusions quotes haemodynamic and symptomatic patency of 71 and 73% at 12 months. Reekers et al. reported similar figures in 40 femoropopliteal occlusions treated by SA, with primary and secondary clinical patency of 59 and 65% at two years. 17 For crural SA, a technical success rate of 86% can be achieved. 18 Reported patency rates for crural lesions are disappointing with haemodynamic and symptomatic 12-month patency rates of 53 and 56% respectively albeit in a small series of 28 limbs. 19 McCarthy et al. recently reported a series of 69 SA cases treated in two centres. 20 For patients with CLI, SA was used if surgery was not considered feasible. This must necessarily skew the results. Only two cases underwent crural SA. The reported technical success rate was 74% with haemodynamic and symptomatic patency of 51 and 60% at 6 months. It would be enlightening to re-examine data from these other studies using the SVS/ISCVS 11 or TASC 6 criteria. In our study, patency rates did not improve after the learning curve. This could reflect confidence in treating more difficult cases but may be influenced by the shorter follow-up in this group, i.e. a smaller sample size.
In terms of workload, SA can reduce the need for early bypass surgery, although later surgery may be required to deal with late reocclusion of the dilated segment. The Leicester group have shown that 42.3% of patients with CLI can be treated with angioplasty alone, with a further 6.3% treated by a combination of bypass and angioplasty. 21 In attempting to hone our own indications for SA, we now consider claudication to be a relative contraindication. Although our morbidity from intervention in claudicants was low, there were three technical failures, of whom two required elective bypass surgery.
In our experience, SA can be performed with good initial technical success and a low risk of major complications. It does not prejudice the success of surgery in the event of a technical failure or a subsequent occlusion. Despite poor patency, excellent limb salvage rates were achieved in patients with CLI, which supports the findings of several studies showing limb salvage despite unreconstructable disease or failed revascularisation. 6 Some patients undoubtedly choose to persist with stable chronic ischaemic ulcers or rest pain rather than undergoing amputation.
In conclusion, fit patients with limb-threatening ischaemia can be offered either surgery or SA, as our results show that there is``nothing to lose'' by using SA as first-line treatment. In the absence of a suitable venous conduit and in patients unfit for anaesthesia or with a limited life expectancy, SA may offer the best chance of avoiding a major amputation. In all cases, careful clinical judgement is required.
